- Home
- APDN vs PCSA Comparison
APDN vs PCSA Comparison
Compare APDN & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APDN
- PCSA
- Stock Information
- Founded
- APDN 1983
- PCSA 2011
- Country
- APDN United States
- PCSA United States
- Employees
- APDN N/A
- PCSA N/A
- Industry
- APDN Other Consumer Services
- PCSA Biotechnology: Pharmaceutical Preparations
- Sector
- APDN Consumer Discretionary
- PCSA Health Care
- Exchange
- APDN Nasdaq
- PCSA Nasdaq
- Market Cap
- APDN 2.7M
- PCSA 3.3M
- IPO Year
- APDN N/A
- PCSA N/A
- Fundamental
- Price
- APDN $4.06
- PCSA $0.22
- Analyst Decision
- APDN
- PCSA Strong Buy
- Analyst Count
- APDN 0
- PCSA 1
- Target Price
- APDN N/A
- PCSA $2.00
- AVG Volume (30 Days)
- APDN 137.8K
- PCSA 5.8M
- Earning Date
- APDN 08-19-2025
- PCSA 08-05-2025
- Dividend Yield
- APDN N/A
- PCSA N/A
- EPS Growth
- APDN N/A
- PCSA N/A
- EPS
- APDN N/A
- PCSA N/A
- Revenue
- APDN $3,790,616.00
- PCSA N/A
- Revenue This Year
- APDN $57.08
- PCSA N/A
- Revenue Next Year
- APDN $40.00
- PCSA N/A
- P/E Ratio
- APDN N/A
- PCSA N/A
- Revenue Growth
- APDN N/A
- PCSA N/A
- 52 Week Low
- APDN $4.04
- PCSA $0.15
- 52 Week High
- APDN $2,655.00
- PCSA $1.58
- Technical
- Relative Strength Index (RSI)
- APDN 33.11
- PCSA 46.61
- Support Level
- APDN $4.04
- PCSA $0.21
- Resistance Level
- APDN $4.64
- PCSA $0.25
- Average True Range (ATR)
- APDN 0.35
- PCSA 0.02
- MACD
- APDN -0.01
- PCSA 0.00
- Stochastic Oscillator
- APDN 1.04
- PCSA 31.16
About APDN Applied DNA Sciences Inc.
Applied DNA Sciences Inc is a biotechnology company developing and commercializing technologies to produce and detect deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company operates in three business segments- Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. It generates majority of its revenue from the MDx Testing Services which is involved in performing and developing clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The company provides its products and services under the brand of Applied DNA Sciences, SigNature molecular tags, SigNature T molecular tags, fiberTyping, SigNify and others.
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).